CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Open Calls for Patient and Clinician Input

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Keytruda (pembrolizumab )

Therapeutic Area: Esophageal carcinoma, gastroesophageal junction adenocarcinoma

Call For Patient Input: April 14, 2021

Patient Input Closed: June 4, 2021

Dupixent (dupilumab)

Therapeutic Area: atopic dermatitis, pediatrics

Call For Patient Input: April 6, 2021

Patient Input Closed: April 23, 2021

Tysabri (natalizumab)

Therapeutic Area: Multiple Sclerosis, relapsing-remitting

Call For Patient Input: April 5, 2021

Patient Input Closed: May 14, 2021

TBC (somatrogon )

Therapeutic Area: Growth hormone deficiency

Call For Patient Input: April 5, 2021

Patient Input Closed: May 28, 2021

TBC (tralokinumab )

Therapeutic Area: atopic dermatitis

Call For Patient Input: March 30, 2021

Patient Input Closed: May 21, 2021

TBC (abrocitinib )

Therapeutic Area: Atopic dermatitis, moderate to severe

Call For Patient Input: March 26, 2021

Patient Input Closed: May 21, 2021

Brukinsa (zanubrutinib)

Therapeutic Area: Waldenström’s macroglobulinemia

Call For Patient Input: March 23, 2021

Patient Input Closed: May 14, 2021

Piqray (alpelisib )

Therapeutic Area: Advanced or Metastatic Breast Cancer.

Call For Patient Input: March 22, 2021

Patient Input Closed: May 14, 2021

MAR-Trientine (Trientine Hydrochloride )

Therapeutic Area: Wilson's Disease

Call For Patient Input: March 18, 2021

Patient Input Closed: May 7, 2021

Perjeta (pertuzumab)

Therapeutic Area: Early stage breast cancer

Call For Patient Input: March 16, 2021

Patient Input Closed: May 7, 2021

Rinvoq (upadacitinib)

Therapeutic Area: atopic dermatitis

Call For Patient Input: March 15, 2021

Patient Input Closed: May 7, 2021

Dojolvi (triheptanoin )

Therapeutic Area: Long-chain fatty acid oxidation disorders

Call For Patient Input: February 26, 2021

Patient Input Closed: April 23, 2021

Tukysa (tucatinib )

Therapeutic Area: Advanced or Metastatic Breast Cancer

Call For Patient Input: February 26, 2021

Patient Input Closed: April 23, 2021

Tagrisso (osimertinib)

Therapeutic Area: Non-small cell lung cancer

Call For Patient Input: February 24, 2021

Patient Input Closed: April 16, 2021